

RESEARCH

Open Access



Is physical therapy recommended for people with parkinson's disease treated with subthalamic deep brain stimulation? a delphi consensus study

Matteo Guidetti¹, Sara Marceglia^{1*}, Tommaso Bocci^{1,2}, Ryan Duncan^{3,4}, Alfonso Fasano^{5,6,7,8}, Kelly D. Foote^{9,10}, Clement Hamani^{11,12,13}, Joachim K. Krauss¹⁴, Andrea A. Kühn^{14,15,16,17,18,19}, Francesco Lena^{20,21}, Patricia Limousin²², Andres M. Lozano^{5,6,23}, Natale V. Maiorana¹, Nicola Modugno²¹, Elena Moro²⁴, Michael S. Okun^{25,26}, Serena Oliveri^{1,2}, Marco Santilli²¹, Alfons Schnitzler^{27,28}, Yasin Temel²⁹, Lars Timmermann³⁰, Veerle Visser-Vandewalle³¹, Jens Volkmann³² and Alberto Priori^{1,2}

Abstract

Background Although deep brain stimulation of the subthalamic nucleus (STN-DBS) induces motor benefits in people with Parkinson's disease (PwPD), its effect on motor axial symptoms (e.g., postural instability, trunk posture alterations) and gait impairments (e.g., freezing of gait) is still ambiguous. Physical therapy (PT) effectively complements pharmacological treatment to improve postural stability, gait performance, and other dopamine-resistant symptoms (e.g. freezing of gait) in the general population with PD. Despite the positive potential of combined PT and STN-DBS surgery, scientific results are still lacking. We therefore involved worldwide leading experts on DBS and motor rehabilitation in PwPD in a consensus Delphi panel to define the current level of PT recommendation following STN-DBS surgery.

Methods After summarizing the few available findings through a systematic scoping review, we identified clinically and academically experienced DBS clinicians (n = 21) to discuss the challenges related to PT following STN-DBS. A 5-point Likert scale questionnaire was used and based on the results of the systematic review, thirty-nine questions were designed and submitted to the panel—half related to general considerations on PT following STN-DBS, and half related to PT treatments.

Results Despite the low-to-moderate quality of data, the few available rehabilitation studies suggested that PT could improve dynamic and static balance, gait performance and posture in the population with PD receiving STN-DBS. Similarly, the panellists strongly agreed that PT might help improve motor symptoms and quality of life, and it may be prescribed to maximize the effects of stimulation. The experts agreed that physical therapists could be part of the multidisciplinary team taking care of the patients. Also, they agreed that conventional PT, but not massage or manual therapy, should be prescribed because of the specificity of STN-DBS implantation.

*Correspondence:

Sara Marceglia
sara.marceglia@unimi.it

Full list of author information is available at the end of the article




© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Conclusions Although RCT evidence is lacking, upon Delphi panel, PT for PwPD receiving STN-DBS can be potentially useful to maximize clinical improvement. However, more research is needed, with RCTs and well-designed studies. The rehabilitation and DBS community should expand this area of research to create guidelines for PT following STN-DBS.

Keywords Deep brain stimulation, DBS, Physiotherapy, Motor rehabilitation, Physical therapy, Delphi consensus, Parkinson's disease, Movement disorders, Neuromodulation

Graphical abstract



Introduction

Deep brain stimulation (DBS) is an established treatment for Parkinson's disease (PD) [1], with subthalamic nucleus (STN) being the most common surgical target

[2]. Although a number of clinical studies suggests long-term improvement in symptoms such as tremor, rigidity, and akinesia [1], the effect of stimulation on motor axial (e.g., postural instability, trunk posture alterations) and

gait impairments (e.g., freezing of gait–FOG) is still unclear [3, 4]. Patients might experience no improvement over time [3, 4], even when stimulation parameters are optimized for appendicular symptoms [1, 3].

Physical therapy (PT) is currently included in the multidisciplinary treatment of PD, but not specifically for patients treated with DBS [5, 6]. PT aims to optimize independence, safety, well-being, and ultimately quality of life, with systematic reviews and meta-analyses confirming PT-induced improvement in motor and non-motor PD impairments [7–9]. In particular, PT effectively complements pharmacological treatment to improve postural stability [7, 10], gait [11, 12], and those symptoms resistant to dopaminergic replacement (e.g. axial motor dysfunctions, FOG) [13, 14] in people with PD (PwPD). Additionally, rehabilitative motor training stimulates a number of neuroplasticity-related events in PwPD [15], including neuronal growth, synaptogenesis, neurotrophic factor expression, and neurogenesis [16–18]. Therefore, PT has the potential to be an effective adjuvant treatment to optimize motor outcomes after deep brain stimulation of the subthalamic nucleus (STN-DBS) surgery. However, this additive effect has not yet been systematically assessed—instead, DBS patients are frequently excluded from exercise trials [19, 20]. Although the current recommendations allow the return to exercise within weeks following surgery, there is no explicit indication for PT [21] and rehabilitative care in clinical settings is led by the personal expertise of physical therapists. Only some insights of safety and effectiveness are currently available, but the studies are characterized by poor methodological rigor and great variability. Therefore, no solid scientific knowledge (e.g., guidelines) is currently available.

Given the potential added value of PT to STN-DBS treatment and the current lack of knowledge, the integration of clinical findings and the experience of leading experts might serve to boost the opening of this field of clinical research and to shape lines of research in it. With these aims, we first performed a systematic scoping review of the articles assessing PT programs in PwPD treated with DBS to summarize the current findings. Then, we asked internationally recognized clinical and academic DBS experts to comment on them and other aspects in a Delphi method-based study [22].

Methods

In this work, we first performed a systematic scoping review to gather the current knowledge on PT protocols in PwPD with DBS. On the basis of the collected results and on the European Physiotherapy Guideline for Parkinson's Disease [23], we created a 5-point Likert scale questionnaire regarding the role of PT and PT

interventions in PwPD with DBS to be answered by clinically and academically experienced DBS clinicians.

Systematic scoping review

A systematic scoping review of clinical research articles was performed according to previous studies, since this type of review allows for a broad overview of topics [24–26]. The literature search was conducted in PubMed/MEDLINE, with the following search keywords: (“deep brain stimulation” OR “DBS”) AND (“physiotherapy” OR “physical therapy” OR “motor rehabilitation” OR “rehabilitation” OR “training” OR “exercise”) AND (“Parkinson's disease” OR “PD”). We considered only clinical studies on PwPD with DBS written in English and published from January 1st, 1994, to June 30th, 2024. Reviews, protocols, simulation studies, conference abstracts or editorials were excluded. Given the paucity of studies on this topic, we decided not to restrict the inclusion criteria further, e.g., considering PwPD who underwent DBS surgery regardless the surgical target (e.g., STN or GPi). After removing duplicates, two independent reviewers (MG and NVM) screened the results of the search based on the titles and abstracts, and then evaluated the full texts of the selected articles. Conflicts were resolved by consensus, if necessary.

The following data were extracted from the selected studies: author, year of publication, study design, characteristics of the subjects, DBS protocol and duration, PT protocol, outcomes and main results. Although the need for quality assessment of selected studies in scoping reviews has been questioned [25], some authors suggest that it improves clarity [27]. Therefore, we performed a quality assessment of the selected studies through the modified version of the Downs and Black checklist [28] (see Table 1 in the Supplementary Materials), which assigns each article a score and evaluation (total score: 11–13, excellent; total score: 9–10, good; total score: 7–8, fair; total score: ≤6, poor).

Questionnaire development

As previously proposed [29], the questionnaire was based upon an extensive review of the literature and the European Physiotherapy Guideline for Parkinson's Disease [23]. From the systematic scoping review, we defined a taxonomy of the outcome measures, and related each of them to an improvement area, and a taxonomy of the PT proposed in published studies. Given the frequency of anatomical targets (STN and GPi) for DBS surgery and treatment in the studies considered in the systematic scoping review (88% STN-DBS, 0.7% GPi-DBS; 11.3% undefined), we decided to refer only to STN-DBS for the creation of the questionnaire for the Delphi

panel. Then, a Steering Committee (SC) of experts ($n=6$) selected within the collaborative network of the leading authors discussed the topics and created a structured questionnaire using a 5-point Likert scale (1=strongly disagree; 2=disagree; 3=undecided; 4=agree; 5=strongly agree) [22]. To do so, the concepts identified in the two taxonomies were translated into two sections of the questionnaire: one is more general and focuses on the opportunity and potential benefits of PT for PwPD receiving STN-DBS; the other, which focuses on the different PT treatments (see Table 2 in Supplementary Materials).

Delphi methodology

The Delphi technique is a multiphase procedure that combines personal viewpoints into a general consensus within a group (panel) [30]. A series of structured questionnaires (rounds) are anonymously completed by experts (panelists) and the responses from each questionnaire fed back in summarized form to the participants [31]. This allows the panelists to reassess their initial judgments, considering the positive aspects of interacting groups (e.g., inclusion of different backgrounds) without the negative ones (e.g., influence of dominant members) [32]. For the purpose of our study, a modified Delphi process [29] was created in three rounds as previously recommended [31]. In rounds one, two and three, the SC together with a broader Experts Panel (EP=15) conducted quantitative assessments to reach a consensus. Electronic questionnaires were utilised in all steps of the process. To prevent confirmation bias, if a statement reached a consensus in either the first or second round, it was not included in the following round; conversely, statements that did not reach a consensus were included in the following round.

The consensus process is mediated by a “facilitator” who was in charge of coordinating the rounds and providing a summary of the responses that should encourage the experts to rethink their scoring. Despite the absence of guidelines, we considered a “consensus reached” when $>80\%$ of the responses fell within the same response label [22]. Since there is no precise standard for defining an “expert” [33], we chose to involve positional leaders in the scientific field (including neurologists, neurosurgeons, physiotherapists) based on the number of peer-reviewed publications [34, 35], as recommended by prior studies [22]. We considered a response rate of $>70\%$ for each round to preserve the rigor of the technique [36]. To highlight the strength of support through each round, we reported the results of each round separately in both textual (median \pm IQR) [32] and graphical representations [33]. As a further analysis, we decided to transform the 5-point Likert scale object of the main analysis into a

3-point Likert scale, i.e., to consider the two highest (4=agree; 5=strongly agree) and lowest (1=strongly disagree; 2=disagree) points as two points (agree and disagree, respectively), while keeping the middle point (undecided). This secondary analysis was performed only for the results of the third round.

Results

Systematic scoping review

Our search yielded 632 articles (Fig. 1 in the Supplementary Materials). Of those, 615 were excluded after reviewing titles and abstracts, while 17 were further assessed as full texts for eligibility. Of these, only 12 met our inclusion criteria [37–48]. The characteristics of the included studies are summarised in Table 1. One was a case series [47], seven were pilot clinical studies [39, 40, 42–46], two were retrospective studies [37, 38], and two were case-controlled studies [41, 48], for a total of 279 patients enrolled. No randomized controlled trials (RCTs) were found. Of these, 245 had STN-DBS (169 bilateral, 76 not specified), 2 had bilateral GPi-DBS, and 32 had DBS with no specified anatomical target. The number of participants per study ranged between 1 [47] and 73 [37], with four studies involving >20 participants [37, 39, 44, 48]. The mean age of participants ranged from 57.6 [44] to 67.6 [43] years, with a mean baseline disease severity ranging from 19.1 (UPDRS, part III) [41] to 105.5 (MDS-UPDRS, part III) [48] and a mean disease duration ranging from 10.5 [46] to 18.8 [43]. Only five studies reported the characteristics of the stimulation [38, 39, 41, 43, 46], and seven studies did not specify the duration of DBS treatment before PT treatment [37–39, 41, 45–47]. As for quality assessment, two studies [44, 48] were classified as presenting good methodological quality, six [37–39, 41–43] as fair, and four [40, 45–47] as poor, according to the Modified Downs and Black Quality Assessment Checklist (see Table 3 in the Supplementary Materials). In general, the studies met the criteria regarding the reporting section, however, a few studies [39, 40, 45–47] did not report the actual probability values of the results, and none provided estimates of random variability for the main outcomes or reported the characteristics of patients lost to follow-up. Owing to the limited sample size, external validity could not be guaranteed for most of the articles. With respect to internal validity, no one clearly stated the potential use of data dredging.

PT outcomes and areas of assessment

The effect of PT interventions was evaluated through various outcomes across the studies, which assessed both motor/functional, biomechanical (e.g., gait analyses) and neurophysiological (e.g., EEG) changes (Table 1). The

Table 1 Studies investigating physical therapy programs in patients with Parkinson's disease and deep brain stimulation

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Cohen et al. [37]	Retrospective study	73 patients (23 F; age, mean [range]: 60.6 [43–80] yo; disease duration mean [range]: 13.6 [3–27] yy; UPDRS—Part III: N.	Bilateral STN (n = 71) and GPi-DBS (n = 2) N.R. duration N.R. parameters	Multi-disciplinary personalized rehabilitation treatment (physical, occupational, and speech therapy + nutritional and psychological support)	UPDRS; FIM Assessments pre- and post- hospitalisation	Significant improvements in motor performances and disability
Nampiaparampil et al. [47]	Case series	Case 1: Male patient (age: 70 yo; disease duration: 7 yy; FIM: 39) Case 2: Male patient with previous pallidotomy (age: 65 yo; disease duration: 15 yy; FIM: 25)	Case 1: bilateral DBS Case 2: bilateral STN-DBS N.R. duration N.R. parameters	Case 1: physical, occupational and speech therapy (once a day, for 6 weeks) Case 2: physical, occupational, and speech therapy (once a day, for 4 weeks)	FIM Assessments pre- and post- hospitalization	Case 1: recovery of walking function with walker, and independency in ADL with assistance Case 2: gait, tremor, and dyskinesia improved
Tassorelli et al. [44]	Pilot, pre-post, clinical study	34 patients (15 F; age, mean \pm SD: 57.6 \pm 9.4 yo; disease duration, mean \pm SD: 11.3 \pm 4.4 yy; UPDRS—Part III, mean \pm SD: 26.8 \pm 12.8)	bilateral STN-DBS n = 13; < 1 month after surgery; n = 8; 1–12 months after surgery; n = 13; > 12 months after surgery N.R. parameters	Personalized protocol: • Cardiovascular warm-up (5–10 min); • Stretching—trunk and limbs (15 min); • Strengthening muscles in a functional context—active-assisted or active isometric and isotonic exercises for trunk and limbs (10–15 min); • Relaxing muscles—especially for the flexor muscles (10 min); • Motor skills, coordination, and dual task performance (10 min); • Balance (10 min); • Gait training—with sensory cues (30 min) Once a day, 5 days a week for 4-to-8 consecutive weeks	UPDRS—Part III; FIM; mBI; MGHFAC; standing balance index Assessments pre- and post-rehabilitative intervention	Significant improvement of motor performance, functional independence, standing balance and independent walking ability

Table 1 (continued)

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Nardo et al. [40]	Pilot, pre-post, clinical study	9 patients (2 F; age, mean \pm SD: 66.44 \pm 5.7 yo; disease duration, mean \pm SD: 12.2 \pm 6 yy; UPDRS—Part III, mean \pm SD: 36.7 \pm 6.4)	DBS (months after surgery, mean \pm SD: 3.11 \pm 1.19) N.R. parameters	Protocol comprising: • Body weight supported and robotic-assisted treadmill training: speed at 1.5 km/h, increased up to 3 km/h as tolerated (45 min) Once a day, for 5 weeks	UPDRS—Part III; Gait kinematics, kinetic, and spatiotemporal parameters Assessments pre- and post-rehabilitative intervention	Significant improvements in gait performance, in all the spatiotemporal gait parameters, and in maximal ankle plantar flexion angle in the toe-off phase
Luna et al. [42]	Cross-over clinical trial	12 patients (5 F; age, mean \pm SD: 61.5 \pm 10.4 yo; disease duration, mean \pm SD: 18.6 \pm 5.2 yy; mH&Y, mean \pm SD: 2.3 \pm 0.3)	bilateral STN-DBS (months after surgery, mean \pm SD: 1.7 \pm 0.6) N.R. parameters	EG; treadmill training with body weight support (30 min) + physical therapy (60 min) CG; treadmill training without body weight support (30 min) + physical therapy (60 min) • Treadmill training: speed at 0.5 km/h, increased by increments of 0.5 km/h as tolerated • Physical therapy: stretching exercise for trunk, upper and lower limbs muscles (2 min); strengthening exercises for upper, lower limbs, trunk, and scapular muscles (for each, 3 sets of 15 repetitions); exercise for balance (bipedal, tandem and unipedal stance—2 sets of each) twice a week for 8 weeks	Gait kinematics, spatiotemporal and angular parameters Assessments pre- and post-rehabilitative intervention	Significant improvements in pelvis' range of motion; hip's range of amplitude; knee flexion on swing phase; and foot progression range of motion (EG group)

Table 1 (continued)

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Bestaven et al. [43]	Pilot, pre-post, clinical study	10 patients (3 F; age, mean \pm SD: 67.6 ± 6.3 yo; disease duration, mean \pm SD: 18.8 ± 4 yy; UPDRS—Part III: N.R.)	bilateral STN-DBS (months after surgery, mean \pm SD: 94.8 ± 37.2 , 60–175 Hz; 60–90 μ s; 2.1–4.6 V)	Protocol comprising: • Stretching exercise for trunk muscles (75 min); • Strengthening exercises for trunk muscles, in extension, flexion and rotation (75 min); • Cardiovascular training (30 min) twice a day, 5 days a week for 4 weeks	UPDRS—Part III; UPDRS—Part III axial score (items 18, 19, 20, 22, 27–30); UPDRS—Part III gait score (item 30); UPDRS—Part III postural instability score (item 29); ABD; BBS; 3D kinematic gait analyses Assessments pre- and post-rehabilitative intervention	Significant improvements in gait performances and posture; significant decrease in daily number of falls
Sato et al. [38]	Retrospective study	16 patients (5 F; age, median \pm IQR: 61.5 ± 9.5 yo; disease duration, median \pm IQR: 13 ± 8 yy; UPDRS—Part III, median \pm IQR: 17.5 ± 7.75)	STN-DBS (median: 130 Hz; 60 μ s; 1.68 V) N.R. duration	Protocol aiming to improve muscle strength, flexibility, balance and gait • Flexibility: active assistive range of motion exercise for ankle, hip, and trunk joints • Strength and balance: dynamic balance exercise in the quadrupedal (cat and dog, diagonal balancing exercise) and standing positions (toe-heel weight bearing, one-leg standing, step position) • Gait: active assistive gait training 40 min a day, for 14 days	Mini-BESTest; TUG; UPDRS-III; BI Assessments before, three days after and 2 weeks after surgery	Significant improvements in balance and gait ability

Table 1 (continued)

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Naro et al. [41]	Case-controlled pilot study	EG: 10 patients with STN-DBS (4 F; age, mean \pm SD: 62 \pm 5 yo; disease duration, mean \pm SD: 15 \pm 2 yy; UPDRS—Part III, mean \pm SD: 19.1 \pm 9.03) CG: 10 patients without DBS (5 F; age, mean \pm SD: 62 \pm 4 yo; disease duration, mean \pm SD: 14 \pm 2 yy; UPDRS—Part III, mean \pm SD: 27.54 \pm 1.12)	bilateral STN-DBS (months after surgery: > 12; 130–240 Hz; 60–120 μ s; 2.2–3.6 V)	EG, CG: RAS-assisted treadmill training (30 min) + physical therapy (60 min) • RAS-assisted treadmill training: bpm at 85 \pm 5 (0.43 m/s), increased by 5 bpm every 3 min up to 120 bpm (0.61 m/s) • Physical therapy: exercises to improve flexibility, balance, gait, and muscular tone and resistance once a day, 6 days a week, for 4 weeks	UPDRS—part III; TUG; 10MWT; BBS; FES; ACE-R; EEG Assessments pre- and post-rehabilitative intervention	EG: Significant improvements in motor performance (self-confidence in balance, sit-to-stand, velocity), walking (velocity), and remodulation of gait cycle—related beta oscillations Both groups: significant improvements in dynamic and static balance, cognitive performance, and the fear of falling
Li et al. [45]	Pilot, clinical study	16 patients (8 F; age, mean \pm SD: 60.25 \pm 5.6 yo; disease duration, mean \pm SD: 10.38 \pm 4.33 yy; MDS-UPDRS—Part III, mean \pm SD: 59.38 \pm 17.07)	bilateral STN-DBS N.R. duration N.R. parameters	Multi-disciplinary treatment (DBS, rehabilitation, medication, psychotherapy), comprising: • Core strength training; • Postural stability training; • Training of sensory function	PDQ-39; MDS-UPDRS—Part III; MDS-UPDRS 3.12; BBS; LoS Assessments pre- and post-surgery, 6 months post-surgery, 12 months post-surgery	Significant improvements in QoL, motor and balance performance at 6 and 12 months
Liang et al. [46]	Pilot, clinical study	15 patients (8 F; age, mean \pm SD: 62.5 \pm 8 yo; disease duration, mean \pm SD: 10.5 \pm 4.47 yy; MDS-UPDRS—Part III, mean \pm SD: 55.06 \pm 16.77)	bilateral STN-DBS (130–170 Hz; 60–90 μ s; 1.5–3.5 V) N.R. duration	Protocol comprising: • Stretching exercises for neck, shoulders, chest, and waist muscles (10 min); • Strengthening of back, posterior shoulder, gluteal muscles (at least 1 set of 10 to 15 repetitions for each); • Back extension and bridge exercise (5 s each); • Education to the patient once per day for 8 weeks	PDQ-39, MDS-UPDRS III, degree of camptocormia Assessments pre-, at 1 month and 6 months after surgery	Significant improvements in camptocormia

Table 1 (continued)

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Sato et al. [39]	Pre-post, clinical study	60 patients (28 F; age, mean \pm SD: 60.7 \pm 8.9 yo; disease duration, mean \pm SD: 12.2 \pm 4.6 yy; MDS-UPDRS—Part III, mean \pm SD: 18.1 \pm 8.6)	STN-DBS (131.2 \pm 6.5 Hz; 58.8 \pm 4.9 μ s; 1.8 \pm 0.5 mA) N.R. duration	General program combining muscle-strengthening exercises, stretching, and balance exercises 40–60 min a day, for 14 days	Mini-BESTest; TUG; TIS; Lower Extremity Extension Torque; 10 Toe-Tapping Seconds; Postural Sway Test Assessments before and three days after surgery, and just before discharge)	Significant improvements in physical function, balance, and gait ability

Table 1 (continued)

Authors, year	Study design	Patients	DBS protocol and duration	PT protocol	Outcomes	Main results
Canesi et al. [48]	Case-controlled pilot study	EG: 22 patients with DBS (9 F; age; median \pm IQR: 63.5 \pm 13.5 yo; disease duration, median \pm IQR: 17 \pm 9 yy; MDS-UPDRS, median \pm IQR: 105.5 \pm 45.55) CG: 25 patients without DBS (9 F; age, median \pm IQR: 69 \pm 11 yo; disease duration, median \pm IQR: 15 \pm 6 yy; MDS-UPDRS, median \pm IQR: 86 \pm 30)	DBS (months after surgery, median \pm IQR: 72 \pm 69.6) N.R. parameters	Multi-disciplinary treatment (occupational therapy, speech therapy), comprising physical therapy: • Morning session: warming-up (passive and active mobilization and active mobilization exercises for both upper and lower limbs—10 min), aerobic exercises (walking and cycling, with intensity between 50 and 80% of the maximal heart rate—15 min), active mobilization exercises and strengthening exercises (60–75% of the estimated 1RM—15 min), postural/proprioceptive exercises (10 min), and cooling down (passive and active mobilization exercises—10 min) • Afternoon session: warming-up (10 min), treadmill (15 min), aerobic exercise (intensity between 50 and 80% of the maximal heart rate—15 min), proprioceptive exercises (15 min) and cooling down (passive and active mobilization exercises—10 min) 60 min, twice a day, 5 days a week for 4 consecutive weeks	MDS-UPDRS; BBS; SPDDS; TUG; 6MWT; MoCA Assessments pre- and 24 h after rehabilitative intervention	EG and CG improved physical functioning and performance, balance function and independence in ADL, but without difference between groups

F = females; yo = years old; yy = years; UPDRS = Unified Parkinson's Disease Rating Scale; STN-DBS = subthalamic nucleus deep brain stimulation; GPi-DBS = globus pallidus internus deep brain stimulation; DBS = deep brain stimulation; N.R. = not reported; FIM = Functional Independence Measure; BI = modified Barthel Index; MGHFAC = Massachusetts General Hospital Functional Ambulation Classification; EG = experimental group; CG = control group; ABD = Activities-specific Balance; BBS = berg balance scale; Mini-BESTest = Mini-Balance Evaluation Systems Test; TUG = Timed Up and Go; BI = Barthel Index; RAS = rhythmic auditory stimulation; 10MWT = 10 m walking test; FES = falls efficacy scale; ACE-R = Addenbrooke's Cognitive Examination-Revised; PDQ-39 = Parkinson's Disease Questionnaire; MDS-UPDRS = Movement Disorder Society-Unified Parkinson's Disease Rating Scale; LoS = Limits of Stability; TIS = Trunk Impairment Scale; SPDDS = Self-Assessment Parkinson Disease Scale; 6MWT = 6 Min Walk Test; MoCA = Montreal Cognitive Assessment

selected studies examined the role of the PT in PwPD undergoing DBS in 5 main areas of assessment: (I) Motor symptoms and motor decline, as assessed mainly through the UPDRS—part III, including its different scores (e.g., axial score and gait score), or the MDS-UPDRS; (II) Gait performance, as assessed mainly through TUG and gait analyses; (III) Balance and postural instability, as assessed mainly through the BBS and the Mini-BESTest; (IV) Quality of life or activities of daily living, as assessed mainly through the FIM and PDQ-39; and (V) Timing of PT treatment, in terms of the number of months after neurosurgery. Although half of the selected studies did not report the time between surgery and rehabilitation [37–39, 45–47], three considered patients with chronic stimulation (e.g., several years) [41, 43, 48], whereas two patients had only a few months of DBS (<1 year) [40, 42]. One study [44] enrolled patients with different timings [44]. As shown in Table 2 in the Supplementary Materials, these areas of assessment were used to build the questionnaire for the Delphi panel.

PT treatments

PT treatments and protocols varied considerably across the selected studies (Table 1). Most of them studied the effect of aerobic training with mobility, stretching, strengthening, balance and gait exercises or a combination thereof [38, 39, 43, 44, 46], whereas four [37, 45, 47, 48] considered a multidisciplinary approach. Among them, only one study [48] reported a clear description of the characteristics of the interventions. Three studies assessed the use of treadmill training: one [40] associated with body weight and robotic support, one [42] with body weight support and physical therapy (stretching, strengthening and balance exercises), and one [41] with rhythmic auditory stimulation. Similarly, PT protocols markedly differed in terms of intensity, frequency, and duration. Only three studies reported the intensity (i.e., session length) of the treatment [38, 39, 48], which ranged from 40 to 60 min. The frequency ranged from twice weekly for 8 weeks [42] to twice a day weekly for 4 weeks [43, 48], for a total duration ranging from 2 [38, 39] to 8 [42, 44, 46] weeks.

Delphi panel results

For the SC, 7 authors were invited but only 6 agreed to participate (response rate: 85.7%). For the EP, of the 20 authors identified, 2 declined to participate and 3 did not reply (response rate: 75%). Therefore, the overall number of the panellists was 21 (overall response rate: 77.7%—see Table 4 in the Supplementary Materials), which is within the recommended range [32]. Demographic characteristics of the panellists are displayed in Table 5 in the Supplementary Materials.

Briefly, most of them were male (81%), between 50 and 59 years old (47.6%) and highly experienced (95.2% and 85.7% with >10 years of experience in neurostimulation field and DBS clinical trials, respectively).

For the 11 general considerations on PT (Table 2), the first round led to no consensus for any of the statements (Fig. 2 in the Supplementary Materials); in the second round, the consensus was reached in three statements (Fig. 1); and finally, in the third round, the consensus was reached in four additional statements (Fig. 2). In the second round, the panellists strongly agreed that PT might help improve motor symptoms (Statement 1) and quality of life (Statement 4) of PwPD undergoing STN-DBS, recommending physical therapists to be part of the multidisciplinary *équipe* taking care of the patients (Statement 11) (for all, 89% strongly agreed, median \pm IQR: 5 ± 0). After the third round, the panellists strongly agreed on the need to prescribe PT to PwPD implanted with STN-DBS as soon as the clinical conditions are stable (Statement 8—94% strongly agreed, median \pm IQR: 5 ± 0) and to chronically-implanted patients (Statement 9—88% strongly agreed, median \pm IQR: 5 ± 0), because it might help maximize the effects of stimulation (Statement 5—88% strongly agreed, median \pm IQR: 5 ± 0). Finally, they suggested that PT be prescribed in treatment guidelines as complementary treatment for PwPD treated with STN-DBS (Statement 10—88% strongly agreed, median \pm IQR: 5 ± 0).

The secondary analysis performed on the third round of answers revealed an agreement on three further statements (Fig. 3 in the Supplementary Materials). Specifically, the experts agreed that PT treatments suggested in the literature for postural instability (Statement 2—94% agreed) and gait disability (Statement 3—88% agreed) for PwPD could also be useful for PwPD under STN-DBS treatment; similarly, they agreed that PT could alleviate the burden of caregivers taking care of these patients (Statement 7—88% agreed).

For the 28 statements on PT treatments (Table 2), no consensus was reached after the first and second rounds (Fig. 4, 5 in the Supplementary Materials). After the third round, consensus was reached in three statements (Fig. 3). Indeed, the panellists agreed on the prescription of conventional PT (i.e., physiotherapist-supervised active exercise interventions targeting gait, balance, transfers or physical capacity, or a combination thereof) as soon as the clinical conditions of the implanted patients are stable (Statement 12—81% strongly agreed, median \pm IQR: 5 ± 0) and in chronically-implanted patients (Statement 13—81% strongly agreed, median \pm IQR: 5 ± 0). Additionally, massage or manual therapy was discouraged as treatment for chronically

Table 2 Five-point Likert questionnaire with the results (median \pm IQR) for each round

Statement*	1st round (n = 20; RR = 95%)	2nd round (n = 18; RR = 86%)	3rd round (n = 16; RR = 76%)
Physical Therapy in PwPD implanted with STN-DBS			
S1. Physical therapy might help improving motor symptoms of PD in PwPD implanted with STN-DBS	5 \pm 1	5 \pm 0–C.R	–
S2. Physical therapy treatments suggested in literature for postural instability in not-implanted PwPD might help improving postural instability also in PwPD implanted with STN-DBS	4 \pm 0.5	4 \pm 0	4 \pm 0
S3. Physical therapy treatments suggested in literature for gait disability in not-implanted PwPD might help improving postural instability also in PwPD implanted with STN-DBS	4 \pm 1	4 \pm 0	4 \pm 0
S4. Physical therapy might help improving quality of life of PwPD implanted with STN-DBS	5 \pm 1	5 \pm 0–C.R	–
S5. Physical therapy might help maximizing effects of stimulation in PwPD implanted with STN-DBS	4 \pm 1	5 \pm 0.75	5 \pm 0–C.R
S6. Physical therapy might help slowing pathological motor decline of PwPD implanted with STN-DBS	4 \pm 1.25	4 \pm 1.75	4 \pm 0.5
S7. Physical therapy might help alleviating caregiver burden of PwPD implanted with STN-DBS	4 \pm 1	4 \pm 0	4 \pm 0
S8. Physical therapy should be prescribed to PwPD implanted with STN-DBS as soon as the clinical conditions are stable	5 \pm 2	5 \pm 0.75	5 \pm 0–C.R
S9. Physical therapy should be prescribed for chronically implanted PwPD with STN-DBS	4 \pm 1.25	5 \pm 1	5 \pm 0–C.R
S10. Physical therapy should be prescribed in treatment guidelines as complementary treatment for PwPD implanted with STN-DBS	5 \pm 1.25	5 \pm 0	5 \pm 0–C.R
S11. Physical therapist should be part of the multidisciplinary équipe taking care of PwPD implanted with STN-DBS	5 \pm 0.25	5 \pm 0–C.R	–
Physical Therapy Treatment in PwPD implanted with STN-DBS			
S12. Conventional physiotherapy (i.e., physiotherapist-supervised active exercise interventions targeting gait, balance, transfers or physical capacity, or a combination thereof) should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 \pm 2	5 \pm 1	5 \pm 0–C.R
S13. Conventional physiotherapy (i.e., physiotherapist-supervised active exercise interventions targeting gait, balance, transfers or physical capacity, or a combination thereof) should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4 \pm 1	5 \pm 0.75	5 \pm 0–C.R
S14. Treadmill training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 \pm 2	4 \pm 1.75	4 \pm 1
S15. Treadmill training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4 \pm 1.25	3.5 \pm 1	3.5 \pm 1
S16. Massage or Manual Therapy should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3 \pm 1.25	2 \pm 1	2 \pm 0
S17. Massage or Manual Therapy should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3 \pm 1	2 \pm 1	2 \pm 0–C.R
S18. Cueing (visual, auditory) should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 \pm 2	4 \pm 1	4 \pm 1.25
S19. Cueing (visual, auditory) should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4 \pm 2	4 \pm 1	4 \pm 1.25
S20. Dance-based training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3 \pm 1.25	3 \pm 2	3 \pm 1
S21. Dance-based training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3 \pm 1	3.5 \pm 2	3 \pm 0.25
S22. Tai Chi-based training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3 \pm 1.25	3 \pm 0	3 \pm 0
S23. Tai Chi-based training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3 \pm 1.25	3 \pm 1	3 \pm 0
S24. Cognitive movement strategies (e.g., stand up right; bring the weight on the heels; transfer the weight to one leg; step out with the other leg, make a large step, and keep on walking) should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 \pm 1	4.5 \pm 1	5 \pm 1
S25. Cognitive movement strategies (e.g., stand up right; bring the weight on the heels; transfer the weight to one leg; step out with the other leg, make a large step, and keep on walking) should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4 \pm 1	4.5 \pm 1	4 \pm 1

Table 2 (continued)

Statement*	1st round (n = 20; RR = 95%)	2nd round (n = 18; RR = 86%)	3rd round (n = 16; RR = 76%)
S26. Aerobic training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	5 ± 2.25	5 ± 1	5 ± 0.25
S27. Aerobic training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	5 ± 2	5 ± 1	5 ± 0.25
S28. Muscle strengthening should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 ± 2	5 ± 1	5 ± 1
S29. Muscle strengthening should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4.5 ± 2	5 ± 1	5 ± 1
S30. Robot-assisted gait training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	2.5 ± 1	2 ± 0.75	2 ± 1
S31. Robot-assisted gait training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	2.5 ± 1	2 ± 0.75	2 ± 1
S32. Aquatic exercise should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3 ± 2	3 ± 1.75	3 ± 1
S33. Aquatic exercise should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3 ± 2.25	3.5 ± 1.75	3 ± 1
S34. Virtual reality and exergames should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3 ± 1.25	3 ± 0.75	3 ± 0.25
S35. Virtual reality and exergames should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3 ± 2	3 ± 1	3 ± 0
S36. Resistance training should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	3.5 ± 1.5	3.5 ± 1.75	3 ± 1
S37. Resistance training should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	3.5 ± 1.25	4 ± 1.75	3 ± 1
S38. Exercise to improve trunk and limbs flexibility and range of motion should be suggested as PT treatment for PwPD implanted with STN-DBS, as soon as the clinical conditions are stable	4 ± 1.25	4 ± 0.75	4 ± 0
S39. Exercise to improve trunk and limbs flexibility and range of motion should be suggested as PT treatment for PwPD chronically implanted with STN-DBS	4 ± 1.25	5 ± 1	4.5 ± 1

*Delphi Panel members were asked to rate their agreement with the statement (1 = strongly disagree; 2 = disagree; 3 = undecided; 4 = agree; 5 = strongly agree); R.R. = response rate; C.R. = consensus reached; PD = Parkinson's disease; PwPD = people with Parkinson's disease; STN-DBS = subthalamic nucleus deep brain stimulation

implanted patients (Statement 17–81% disagreed, median ± IQR: 2 ± 0).

The secondary analysis performed on the third round of answers revealed an agreement on several other statements (Fig. 6 in the Supplementary Materials). Specifically, the experts agreed that PwPD implanted with STN-DBS, regardless of time, should be prescribed cognitive movement strategies (Statement 24–100% agree; Statement 25–100% agree), aerobic training (Statement 26–94% agree; Statement 27–94% agree), muscle strengthening (Statement 28–81% agree; Statement 29–81% agree), and exercise to improve trunk and limb flexibility and range of motion (Statement 38–88% agree; Statement 39–88% agree). Conversely, the experts did not recommend robot-assisted gait training (Statement 30–81% disagree; Statement 31–94% disagree) and massage or manual therapy as soon as the clinical conditions are stable (Statement 16–81% disagree).

Discussion

To answer the question of the use of PT in PwPD receiving STN-DBS, in this study, after summarizing the current scientific knowledge, we asked the opinion of clinical and academic DBS experts applying a Delphi methodology. The 21 experts agreed that PT might maximize the effects of stimulation, improving both motor symptoms and quality of life. PT should be prescribed in treatment guidelines in the form of conventional physiotherapy (i.e., physiotherapist-supervised active exercise interventions targeting gait, balance, transfers or physical capacity, or a combination thereof), and physical therapists should be part of the multidisciplinary équipe taking care of PwPD implanted with STN-DBS. However, massage or manual therapy should not be suggested.

PT or no PT?

Considering the caveats and methodological limitations found in the systematic scoping review, it might be only




Fig. 1 Percentage of agreement for the 11 general considerations on physical therapy after subthalamic nucleus deep brain stimulation in patients with Parkinson's disease (Statement 1–11) among the Delphi Panel members, as result of the second round. Statement 1, Statement 4 and Statement 11 reached a consensus, i.e., 89% of the responses fell within the response label "strongly agree". PD = Parkinson's disease; STN-DBS = subthalamic nucleus deep brain stimulation; S = statement

qualitatively argued that PT for PwPD treated with STN-DBS could improve dynamic and static balance [38, 39, 41, 44, 45, 48], gait performance [38–44] and posture [43], ultimately leading to a significant decrease in the daily number of falls [43] and the fear of falling [41], with an increase in motor performance [37, 39, 41, 44, 45, 48], functional independence [37, 44, 48], and quality of life [45]. Therefore, our expert consensus is highly important for establishing whether PT should be potentially beneficial for PwPD treated with STN-DBS. The experts agreed that PT might improve motor symptoms and quality of life, maximizing the effects of electrical stimulation. Additionally, in our secondary analysis, the experts considered that PT could be helpful for caregivers, and that PT treatments already suggested for postural instability and gait disability in PwPD could also be effective for PwPD receiving STN-DBS, in line with the limited number of clinical studies [38–44, 46, 48].

Although STN-DBS has been demonstrated to be highly effective at controlling motor symptoms in PwPD [49], some clinical issues remain open. After initial improvement following STN-DBS [50, 51], postural instability [52] and gait disturbances [53, 54] have been reported to worsen over time [55]. Some findings even

suggest no significant improvement in trunk rigidity [56]. Although it is not clear whether this deterioration might be due to PD progression rather than DBS treatment, taken together, this worsening might determine physical inactivity, increase in falls [57], and secondary complications [58] after STN-DBS surgery. On the other hand, solid scientific knowledge confirms that PT maximizes independence, well-being, and quality of life [59, 60], in addition to improving motor (such as postural instability [7, 10], gait impairments such as festination, FOG [13, 14]) and non-motor (e.g., depression, apathy, and fatigue [8, 9]) PD symptoms. It is reasonable to hypothesize that this evidence in the general PD population would also apply to PwPD implanted with STN-DBS, where exercise and STN-DBS might exert a complimentary, positive effects on PD severity and mobility. This coupled effect has already been shown for exercise and dopaminergic medication on muscle force production, UPDRS III scores, and mobility in PwPD [61]. Finally, both STN-DBS [62] and PT [15] were suggested to stimulate a number of neuroplastic and neuroprotective biochemical events in PwPD. For example, while STN-DBS could preserve nigral dopamine neurons from degeneration [63, 64] and increase the level of neurotrophic factors in the nigrostriatal




Fig. 2 Percentage of agreement for the 11 general considerations on physical therapy after subthalamic nucleus deep brain stimulation in patients with Parkinson's disease (Statement 1–11) among the Delphi Panel members, as result of the third round. Statement 5, Statement 8, Statement 9 and Statement 10 reached a consensus, i.e., respectively, 88%, 94%, 88% and 88% of the responses fell in the response label "strongly agree". PD = Parkinson's disease; STN-DBS = subthalamic nucleus deep brain stimulation; S = statement

system and primary motor cortex [65], PT and exercise would increase neuronal growth, synaptogenesis, neurotrophic factor expression, and neurogenesis [16–18]. The combination of STN-DBS and PT in PwPD could boost these neurochemical mechanisms and biological pathways, attenuating disease progression and enhancing compensatory neuronal strategies. However, all these assumptions remain speculative, and no data are available—which is likely why experts couldn't reach an agreement on this.

PT prescription

The panel agreed that PT should be prescribed for PwPD implanted with STN-DBS, both in post-acute and chronic phases. Additionally, they suggested that PT should be included in treatment guidelines, and that physical therapists should be involved in the multidisciplinary team in charge of patients. The low-risk nature of PT coupled with the potential benefit for improving motor function and quality of life in PwPD with STN-DBS supports these statements. According to the studies selected in our systematic scoping review, PT

in these patients might be well tolerated—although the duration of the rehabilitation period might be an obstacle for completion [40]. Additionally, PT appears to be safe, with several studies reporting no intervention-related adverse effects [41, 42]. For example, Bestaven et al. [43] reported that, despite initial doubts and apprehension, all the enrolled subjects agreed with and completed the PT protocol. Also, current recommendations allow patients to return to exercise within weeks following surgery [66]; therefore, it appears that PT should be considered a nonharmful intervention for PwPD with STN-DBS, even more so because PT is commonly a supervised treatment. Indeed, physical therapists could contribute to the care of patients after implantation surgery (e.g., in the management of complications after surgery [67] or during the adaptation of stimulation parameters [67]) or in the chronic phase (e.g., modifying pathological movement patterns [68] or teaching patients to adapt motor strategies and relevant activities of daily living to the new conditions [68]). In addition to the technical aspects of intervention, PT treatment characteristically requires multiple sessions for quite long periods—a time




Fig. 3 Percentage of agreement for the 28 statements on physical therapy treatments after subthalamic nucleus deep brain stimulation in patients with Parkinson's disease (Statement 12–39) among the Delphi Panel members, as result of the third round. Statement 12 and Statement 13 reached a consensus, i.e., for both, 81% of the responses fell in the response label “strongly agree”. Statement 17 reached a consensus, i.e., 81% of the responses fell in the response label “disagree”. PD = Parkinson's disease; STN-DBS = subthalamic nucleus deep brain stimulation; S = statement

where patient-therapist relationship can be developed for explanations or counselling. This could represent an occasion to increase the cooperation and motivation of patients and caregivers, which is fundamental to achieve a good outcome after DBS [69].

PT protocols

Despite the very limited scientific knowledge found in the systematic scoping review, the panellists agreed that conventional PT should be prescribed to PwPD implanted with STN-DBS, regardless of the time from surgery. Interestingly, when the experts' opinions were reconsidered on a 3-point Likert scale, several PT treatments were also considered effective for PwPD receiving STN-DBS—cognitive movement strategies, aerobic training, muscle strengthening, and exercise to improve trunk and limbs flexibility and range of motion.

The results on conventional PT-like interventions [38, 39, 42–44, 46, 48] as shown by our systematic scoping review, suggest a positive effect on motor and functional PD symptoms. A number of findings

suggest similar effects for the general PD population [9], although without superiority over other types of treatment [70]. For example, several studies suggest that multifactorial conventional PT interventions including muscle strengthening, increasing of range of movement, balance training and gait training have positive effects on balance dysfunction and postural instability in PwPD [15, 71]. Additionally, balance training improves self-confidence while performing activities of daily living and reduces the fall rate [21], whereas gait training improves FOG, gait speed and step length, even months after the treatment [11, 14]. PwPD with STN-DBS implants might benefit from the same evidence observed in the general PD population. In addition, robust evidence suggests that other recommended PT treatments reduce PD motor symptom severity and improve motor function in PwPD [72–75]. Recently, various forms of aerobic training (treadmill walking, stationary cycling) have shown to slow motor progression in PwPD who are not yet on dopaminergic medication [76, 77].

On the other hand, the panellists agreed that massage or manual therapy should not be applied in chronically implanted patients, nor should robot-assisted gait training be recommended. While no evidence is currently available in PwPD treated with STN-DBS, a systematic review suggests that the evidence in the general PD population is limited and conflicting in some cases due to methodological concerns [78]. The European Physiotherapy Guideline for Parkinson's disease released a weak recommendation for using massage or manual therapy to reduce pain and muscular spasms, but highlighted the need to always combine it with other types of interventions as no evidence supports their use to improve physical and functional performance [23]. Conversely, the literature reports encouraging results [38, 40–42] of robot-assisted gait training, including in PwPD [79].

Rehabilitative considerations

In PwPD under STN-DBS treatment, motor [80, 81] and functional [82] strategies established in years of disease need to be readapted after the rapid changes induced by the stimulation. This requires the active involvement of the patient in a rehabilitation pathway to optimize the benefits of DBS. For example, pathological movement patterns typical of gait in PD [83] need to be gradually adapted to improve the mobility achieved by STN-DBS [68]. Additionally, since STN-DBS is a symptomatic but not resolute treatment, PwPD receiving STN-DBS might need PT treatment during their lifetime. It was proposed that general motor rehabilitation principles studied for PwPD, such as personalizing motor strategies and applying motor learning techniques (e.g., repetition, task-specific training) [84], are applicable to those PwPD undergoing DBS [68]. However, some differences from the general PD population critical for PT programs might be considered:

- I. *Pre-surgery characteristics of the patients.* PwPD candidates for STN-DBS surgery have a confirmed diagnosis of idiopathic PD, are young (younger than 69 years but may be older) and have no or little cognitive dysfunction [69, 85]. From a pharmacological point of view, these patients strongly respond to dopamine medication and have complications of levodopa therapy (e.g., dyskinesias, on–off fluctuations) [85, 86]. These criteria create a particular subgroup of the PD population, whose characteristics must be considered when planning PT interventions.
- II. *Actual clinical characteristics of the patients.* A new, DBS-induced phenotype of PD was proposed, where tremor, rigidity, bradykinesia, on–off

fluctuations and dyskinesias are well-controlled, but gait impairments, postural instability and abnormalities are still present [49]. Therefore, these should be the primary targets of PT interventions. In addition, stimulation-induced side effects need to be considered, such as dysphagia [3] and speech disorders (e.g., dysarthria) [87], cognitive (e.g., alteration of verbal fluency) [88, 89], psychological (e.g., impulsivity, depression) [90] and autonomic (e.g., constipation, swallowing) [90, 91] impairments. Besides motor rehabilitation, also other rehabilitative health professions [91] (e.g., speech therapy, occupational therapy, neuropsychology) could be involved and treatment tested.

- III. *Presence of hardware.* A systematic review of hardware-related complications of DBS reported that lead migration or dislocation (0–19% of interventions) and fracture or failure of some parts of the DBS system (0–15% of interventions) are among the most common complications after DBS surgery [57, 92]. Therefore, although PT programs appear to be safe, a more intensive research program must consider hardware presence and frailty. In addition, the use of any physical forces (e.g., magnetic fields) that could interfere with DBS components should be avoided.
- IV. *Interaction between stimulation and PT.* In light of the opportunities given by advanced DBS technologies [93, 94] such as adaptive DBS [95], it is likely that patients might need specific DBS programming while undergoing PT sessions to increase their performance and optimize benefits. This should be a further research topic to be considered as physiotherapists and DBS experts interact to develop effective and personalized rehabilitation programs.

Limitations

The panel conclusions should not be viewed as a replacement for clinical judgment or original research; rather, our results are relevant mostly in terms of future research directions, which will foster the development of the field of rehabilitation after STN-DBS in PwPD. Indeed, they are based on the collective expertise of a panel of experts who can draw on both their personal experience and scientific knowledge—even more so that our panel was gender- and nation- imbalanced (majority was male, and all experts coming from North America or Europe). Consensus-based results provide only a level 4 evidence being expert opinions [96, 97], which represents the lowest level of evidence [98]. Also,

one should consider that our panel was geographically. More discussion and empirical evidence coming from methodologically precise studies (e.g., RCTs) are needed to support the feasibility of our results, especially considering that other common stimulation targets (e.g., the GPi) were not considered in this study.

Conclusion

Despite the limited, low-quality knowledge currently available on the role of PT in PwPD and STN-DBS, the panellists agreed that PT could improve the motor symptoms and quality of life of these patients and should be considered as part of management in the form of conventional PT, as part of the management guidelines. In conclusion, the PT is a safe intervention that can be prescribed to PwPD receiving STN-DBS to maximize clinical improvements. Even though providing only level 4 evidence, this Delphi consensus represents a call to both the motor rehabilitation (but also occupational, speech and neuropsychological) and DBS community to start working and interacting to deepen this field of research. Well-designed and well-performed clinical trials (e.g., blinded RCT) could provide high-level evidence for PT, for example verifying whether current guidelines are applicable to this population or whether specific treatments can be of support clinical care, which for years has been relegated to the personal expertise of physical therapists despite the increasing number of PwPD implanted with STN-DBS.

Abbreviations

DBS	Deep brain stimulation
PD	Parkinson's disease
STN	Subthalamic nucleus
STN-DBS	Deep brain stimulation of the subthalamic nucleus
GPI	Globus pallidus internus
GPI-DBS	Deep brain stimulation of globus pallidus internus
FOG	Freezing of gait
PT	Physical therapy
PwPD	People with Parkinson's disease
SC	Steering committee
EP	Experts panel
UPDRS	Unified Parkinson's Disease Rating Scale
MDS-UPDRS	Movement Disorder Society—Unified Parkinson's disease rating scale
TUG	Timed up and go
BBS	Berg balance scale
Mini-BESTest	Mini Balance Evaluation Systems Test
FIM	Functional Independence Measure
PDQ-39	Parkinson's Disease Questionnaire—39

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12984-025-01616-w>.

Additional file 1.

Acknowledgements

The authors acknowledge Dr. Briselda Doka, who contributed to the early stages of the literature research and data handling.

Author contributions

M.G., F.L., M.S., A.P., N.M., and R.D. performed the conceptualization. M.G., S.M., T.B., N.V.M., F.L., M.S., A.P., N.M., R.D., A.S., A.F., A.A.K., A.M.L., C.H., E.M., J.V., J.K.K., K.D.F., L.T., S.O., M.S.O., P.L., V.V.V., and Y.T. performed the investigation. M.G. and S.M. drafted and wrote the main manuscript text. M.G., S.M., and N.V.M. performed the experimental data acquisition and statistical analysis. M.G. prepared the result visualization. A.P. and S.M. were responsible for validation, reviewing, and editing the original work. M.G., S.M., T.B., N.V.M., F.L., M.S., A.P., N.M., R.D., A.S., A.F., A.A.K., A.M.L., C.H., E.M., J.V., J.K.K., K.D.F., L.T., S.O., M.S.O., P.L., V.V.V., and Y.T. reviewed and edited the original work. All authors read and approved the submitted version of the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

A.F. has received payments as consultant and/or speaker from Abbott, Boston Scientific, Ceregate, Inbrain Neuroelectronics, Medtronic, Iota and has received research support from Boston Scientific, Medtronic; K.D.F. reports receiving research support and fellowship support from Medtronic and Boston Scientific and research support from Functional Neuromodulation; J.K.K. is a consultant to Medtronic, Boston Scientific, aleva and Inomed; A.A.K. is a consultant to Medtronic, Boston Scientific and Teva; A.M.L. is a consultant to Abbott, Boston Scientific, Insightec, Medtronic and Functional Neuromodulation (Scientific Director). EM has received an educational grant from Boston Scientific and honoraria from Medtronic and Newronika; M.S.O. serves as Medical Advisor in the Parkinson's Foundation, and has received research grants from NIH, Parkinson's Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. M.S.O.'s research is supported by: R01 NS131342 NIH R01 NR014852, R01NS096008, UH3NS119844, U01NS119562. M.S.O. is PI of the NIH R25NS108939 Training Grant. M.S.O. has received royalties for publications with Hachette Book Group, Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge (movement disorders books). M.S.O. is an associate editor for New England Journal of Medicine Journal Watch Neurology and JAMA Neurology. M.S.O. has participated in CME and educational activities (past 12–24 months) on movement disorders sponsored by WebMD/Medscape, RMEI Medical Education, American Academy of Neurology, Movement Disorders Society, Mediflix and by Vanderbilt University. The institution and not M.S.O. receives grants from industry. M.S.O. has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations; A.S. received consulting fees from Abbott, Zambon, and Abbvie, and speaker honoraria from bsh medical communication, Abbott, Kyowa Kirin, Novartis, Abbvie, and Alexion, GE Healthcare. The institution of A.S., not A.S. personally, received funding by the Deutsche Forschungsgemeinschaft, the Brunhilde Moll Foundation, and Abbott; L.T. received occasional payments as a consultant for Boston Scientific, L.T. received honoraria as a speaker on symposia sponsored by Boston Scientific, AbbVIE, Novartis, Neuraxpharm, Teva, the Movement Disorders Society und DIAPLAN. The institution of L.T., not L.T. personally, received funding by Boston Scientific, the German Research Foundation, the

German Ministry of Education and Research, the Otto-Loewi-Foundation and the Deutsche Parkinson Vereinigung. Neither L.T. nor any member of his family holds stocks, stock options, patents or financial interests in any of the above-mentioned companies or their competitors. L.T. serves as the president of the German Neurological Society without any payment or any income; V.V.V. received occasional payments as a consultant or speaker on symposia from Boston Scientific and Medtronic. J.V. reports grants and personal fees from Medtronic, grants and personal fees from Boston Scientific, personal fees from Abbott outside the submitted work. J.V. was supported by the German Research Foundation (DFG, Project-ID424778381, TRR 295)—J.V. received consulting and lecture fees from Boston Scientific, Medtronic and Newronika, research grants from the German Research Foundation, the German Ministry of Research and Education, Boston Scientific and Medtronic, lecture Honoraria from UCB, Zambon, Abbott; A.P. and S.M. are founders and shareholders of Newronika Spa, Italy; All the other authors declare no competing interests.

Author details

¹Aldo Ravelli* Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudini 8, 20142 Milan, MI, Italy. ²Clinical Neurology Unit, "Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo", Department of Health Sciences, University of Milan, Via Antonio di Rudini 8, 20142 Milan, Italy. ³School of Medicine, Program in Physical Therapy, Washington University in St. Louis, St. Louis, MO, USA. ⁴School of Medicine, Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA. ⁵Krembil Research Institute, University Health Network, Toronto, ON, Canada. ⁶CRANIA Center for Advancing Neurotechnological Innovation to Application, University of Toronto, Toronto, ON, Canada. ⁷KITE, University Health Network, Toronto, ON, Canada. ⁸Edmond J. Safra Program in Parkinson's Disease Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Division of Neurology, University of Toronto, Toronto, ON, Canada. ⁹Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, 3011 SW Williston Rd, Gainesville, FL 32608, USA. ¹⁰Department of Neurosurgery, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA. ¹¹Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. ¹²Harquail Centre for Neuromodulation, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. ¹³Department of Surgery, University of Toronto, 149 College Street, Toronto, ON M5T 1P5, Canada. ¹⁴Department of Neurosurgery, Hannover Medical School, Hannover, Germany. ¹⁵Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. ¹⁶Bernstein Center for Computational Neuroscience, Humboldt-Universität, Berlin, Germany. ¹⁷NeuroCure, Exzellenzcluster, Charité-Universitätsmedizin Berlin, Berlin, Germany. ¹⁸DZNE, German Center for Neurodegenerative Diseases, Berlin, Germany. ¹⁹Berlin School of Mind and Brain, Humboldt-Universität Zu Berlin, Berlin, Germany. ²⁰Department of Medicine and Health, University of Molise, 86100 Campobasso, Italy. ²¹IRCCS INM Neuromed, 86077 Pozzilli, Italy. ²²Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK. ²³Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. ²⁴Division of Neurology, CHU of Grenoble, Grenoble Institute of Neurosciences, INSERM U1216, Grenoble Alpes University, Grenoble, France. ²⁵Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, USA. ²⁶Department of Neurosurgery, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, USA. ²⁷Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany. ²⁸Department of Neurology, Center for Movement Disorders and Neuromodulation, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany. ²⁹Department of Neurosurgery, Maastricht University Medical Center, Maastricht, Netherlands. ³⁰Department of Neurology, University Hospital of Marburg, Marburg, Germany. ³¹Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. ³²Department of Neurology, University Hospital Würzburg, Würzburg, Germany.

Received: 16 December 2024 Accepted: 26 March 2025
Published online: 10 April 2025

References

- Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. *Nat Rev Neurol*. 2019;15(4):234–42.
- Prasad AA, Wallén-Mackenzie Å. Architecture of the subthalamic nucleus. *Commun Biol*. 2024;7(1):1–14.
- Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. *Nat Rev Neurol*. 2015;11(2):98–110.
- Krack P, Martínez-Fernández R, del Alamo M, Obeso JA. Current applications and limitations of surgical treatments for movement disorders. *Mov Disord*. 2017;32(1):36–52.
- Rubénis J. A rehabilitational approach to the management of Parkinson's disease. *Parkinsonism Relat Disord*. 2007;13(SUPPL. 3):S495–7.
- Playfer JR, Hindle JV. Rehabilitation and the interdisciplinary team. 2018;291–313.
- Tomlinson CL, Patel S, Meek C, Clarke CE, Stowe R, Shah L, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. The Cochrane database of systematic reviews. 11 luglio 2012 [citato 12 maggio 2022];(7). Disponibile su: <https://pubmed.ncbi.nlm.nih.gov/22786482/>
- Okada Y, Ohtsuka H, Kamata N, Yamamoto S, Sawada M, Nakamura J, et al. Effectiveness of long-term physiotherapy in parkinson's disease: a systematic review and meta-analysis. *J Parkinson's Dis*. 2021;11(4):1619–30.
- Radder DLM, Lúcia Silva de Lima A, Domingos J, Keus SHJ, van Nimwegen M, Bloem BR, et al. Physiotherapy in Parkinson's disease: a meta-analysis of present treatment modalities. *Neurorehab Neural Repair*. 2020;34(10):871–80.
- Abbruzzese G, Marchese R, Avanzino L, Pelosin E. Rehabilitation for Parkinson's disease: current outlook and future challenges. *Parkinsonism Relat Disord*. 2016;22(Suppl 1):S60–4.
- Bello O, Sanchez JA, Lopez-Alonso V, Márquez G, Morenilla L, Castro X, et al. The effects of treadmill or overground walking training program on gait in Parkinson's disease. *Gait Posture*. 2013;38(4):590–5.
- Smania N, Corato E, Tinazzi M, Stanzani C, Fiaschi A, Girardi P, et al. Effect of balance training on postural instability in patients with idiopathic Parkinson's disease. *Neurorehab Neural Repair*. 2010;24(9):826–34.
- Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. *Mov Disord*. 2011;26(S3):S2–41.
- Cosentino C, Baccini M, Putzolu M, Ristori D, Avanzino L, Pelosin E. Effectiveness of physiotherapy on freezing of gait in parkinson's disease: a systematic review and meta-analyses. *Mov Disord Off J Mov Disord Soc*. 2020;35(4):523–36.
- Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. *Arch Phys Med Rehabil*. 2003;84(8):1109–17.
- Polcastro G, Brunelli M, Tinazzi M, Chiamulera C, Emerich DF, Paolone G. Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinson's Disease. *Neural plasticity*. 2020 [citato 12 maggio 2022];2020. Disponibile su: <https://pubmed.ncbi.nlm.nih.gov/33293946/>
- Malczyńska-Sims P, Chalimoniuk M, Sulek A. The effect of endurance training on brain-derived neurotrophic factor and inflammatory markers in healthy people and Parkinson's disease. A narrative review. *Front Physiol*. 2020 [citato 12 maggio 2022];11. Disponibile su: <https://pubmed.ncbi.nlm.nih.gov/33329027/>
- Torikoshi S, Morizane A, Shimogawa T, Samata B, Miyamoto S, Takahashi J. Exercise promotes neurite extensions from grafted dopaminergic neurons in the direction of the dorsolateral striatum in Parkinson's disease model rats. *J Parkinson's Dis*. 2020;10(2):511–21.
- Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. *Neurorehab Neural Repair*. 2012;26(2):132–43.
- Prodoehl J, Rafferty MR, David FJ, Poon C, Vaillancourt DE, Comella CL, et al. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. *Neurorehab Neural Repair*. 2015;29(2):112–22.
- Smania N, Corato E, Tinazzi M, Stanzani C, Fiaschi A, Girardi P, et al. Effect of balance training on postural instability in patients with idiopathic Parkinson's disease. *Neurorehab Neural Repair*. 2010;24(9):826–34.

22. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. *Pract Assess Res Eval*. 2007;12(1):10.
23. Keus S, Munneke M, Graziano M, Paltamäa J, Pelosin E, Domingos J, et al. European Physiotherapy Guideline for Parkinson's Disease Developed with twenty European professional associations. 2014 [citato 13 maggio 2022]; Disponibile su: www.parkinsonnet.info/euguideline
24. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. 2005;8(1):19–32.
25. Pham MT, Rajić A, Greig JD, Sargeant JM, Papadopoulos A, McEwen SA. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. *Res Synth Methods*. 2014;5(4):371–85.
26. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci*. 2010;5:69.
27. Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol* dicembre. 2014;67(12):1291–4.
28. Price OJ, Sewry N, Schwellnus M, Backer V, Reier-Nilsen T, Bougault V, et al. Prevalence of lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus group on 'acute respiratory illness in the athlete'. *Br J Sports Med*. 2022;56(4):213–22.
29. Kerlinger FN. *Foundations of Behavioral Research* New York: Holt. Rinehart & Winston. 1973;
30. Lynn MR, Layman EL, Englehardt SP. Nursing administration research priorities. A national Delphi study. *J Nurs Adm*. 1998;28(5):7–11.
31. Ludwig B. Predicting the future: Have you considered using the Delphi methodology? *J Ext*. 1997;35:15.
32. Rowe G, Wright G. Expert Opinions in Forecasting: The Role of the Delphi Technique. In: Armstrong JS, curatore. *Principles of Forecasting: A Handbook for Researchers and Practitioners* [Internet]. Boston, MA: Springer US; 2001 [citato 9 giugno 2023]. p. 125–44. (International Series in Operations Research & Management Science). Disponibile su: https://doi.org/10.1007/978-0-306-47630-3_7
33. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs*. 2000;32(4):1008–15.
34. Meyer JH. Rethinking the outlook of colleges whose roots have been in agriculture. 1992.
35. Miller G. The development of indicators for sustainable tourism: results of a Delphi survey of tourism researchers. *Tour Manage*. 2001;22(4):351–62.
36. Sumsion T. The Delphi technique: an adaptive research tool. *Br J Occup Ther*. 1998;61(4):153–6.
37. Cohen DB, Oh MY, Baser SM, Angle C, Whiting A, Birk C, et al. Fast-track programming and rehabilitation model: a novel approach to postoperative deep brain stimulation patient care. *Arch Phys Med Rehabil*. 2007;88(10):1320–4.
38. Sato K, Aita N, Hokari Y, Kitahara E, Tani M, Izawa N, et al. Balance and gait improvements of postoperative rehabilitation in patients with Parkinson's disease treated with subthalamic nucleus deep brain stimulation (STN-DBS). *Parkinsons Dis*. 2019;2019:7104071.
39. Sato K, Hokari Y, Kitahara E, Izawa N, Hatori K, Honaga K, et al. Short-term motor outcomes in parkinson's disease after subthalamic nucleus deep brain stimulation combined with post-operative rehabilitation: a pre-post comparison study. *Parkinsons Dis*. 2022;2022:8448638.
40. Nardo A, Anasetti F, Servello D, Porta M. Quantitative gait analysis in patients with Parkinson treated with deep brain stimulation: the effects of a robotic gait training. *NeuroRehabilitation*. 2014;35(4):779–88.
41. Naro A, Pignolo L, Sorbera C, Latella D, Billeri L, Manuli A, et al. A case-controlled pilot study on rhythmic auditory stimulation-assisted gait training and conventional physiotherapy in patients with Parkinson's disease submitted to deep brain stimulation. *Front Neurol*. 2020;11:794.
42. Luna NMS, Lucareli PRG, Sales VC, Speciali D, Alonso AC, Peterson MD, et al. Treadmill training in Parkinson's patients after deep brain stimulation: effects on gait kinematic. *NeuroRehabilitation*. 2018;42(2):149–58.
43. Bestaven E, Guillaud E, De Sèze M, Jerome A, Burbaud P, Cazalets JR, et al. Effect of trunk muscle strengthening on gait pattern and falls in Parkinson's disease. *J Rehabil Med Clin Commun*. 2019;2:1000003.
44. Tassorelli C, Buscone S, Sandrini G, Pacchetti C, Furnari A, Zangaglia R, et al. The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a pilot study. *Parkinsonism Relat Disord* novembre. 2009;15(9):675–81.
45. Li H, Liang S, Yu Y, Wang Y, Cheng Y, Yang H, et al. Clinical experience of comprehensive treatment on the balance function of Parkinson's disease. *Medicine (Baltimore)*. 2020;99(19):e20154.
46. Liang S, Yu Y, Li H, Wang Y, Cheng Y, Yang H. The study of subthalamic deep brain stimulation for Parkinson disease-associated camptocormia. *Med Sci Monit*. 2020;26:e919682.
47. Nampiaparampil DE, Kuppy JE, Nampiaparampil GM, Salles SS. Inpatient rehabilitation after deep brain stimulator placement: a case series. *Parkinsonism Relat Disord*. 2008;14(4):356–8.
48. Canesi M, Lippi L, Rivaloli S, Vavassori D, Trenti M, Sartorio F, et al. Long-term impact of deep brain stimulation in Parkinson's disease: Does it affect rehabilitation outcomes? *Medicina*. 2024;60(6):927.
49. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, et al. Deep brain stimulation: current challenges and future directions. *Nat Rev Neurol*. 2019;15(3):148–60.
50. Rocchi L, Chiari L, Horak FB. Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2002;73(3):267–74.
51. Rocchi L, Chiari L, Cappello A, Gross A, Horak FB. Comparison between subthalamic nucleus and globus pallidus internus stimulation for postural performance in Parkinson's disease. *Gait Posture*. 2004;19(2):172–83.
52. St George RJ, Carlson-Kuhta P, Burchiel KJ, Hogarth P, Frank N, Horak FB. The effects of subthalamic and pallidal deep brain stimulation on postural responses in patients with Parkinson disease. *J Neurosurg*. 2012;116(6):1347–56.
53. Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, et al. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. *Neurology*. 2015;84(4):415–20.
54. Moreau C, Defebvre L, Destée A, Bleuse S, Clement F, Blatt JL, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. *Neurology*. 2008;71(2):80–4.
55. St. George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. *Neurology*. 2010;75(14):1292–9.
56. Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes of surgical therapies for Parkinson's disease. *Mov Disord*. 2012;27(14):1718–28.
57. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA*. 2009;301(1):63–73.
58. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. *Mov Disord Off J Mov Disord Soc*. 2004;19(8):871–84.
59. Keus SHJ, Bloem BR, Hendriks EJM, Bredero-Cohen AB, Munneke M. Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research. *Mov Disord*. 2007;22(4):451–60.
60. Osborne JA, Botkin R, Colon-Semenza C, DeAngelis TR, Gallardo OG, Kosakowski H, et al. Physical therapist management of parkinson disease: a clinical practice guideline from the american physical therapy association. *Phys Ther*. 2022;102(4):pzab302.
61. Dibble LE, Foreman KB, Addison O, Marcus RL, LaStayo PC. Exercise and medication effects on persons with parkinson disease across the domains of disability: a randomized clinical trial. *J Neurol Phys Ther*. 2015;39(2):85.
62. Guidetti M, Bertini A, Pirone F, Sala G, Signorelli P, Ferrarese C, et al. Neuroprotection and non-invasive brain stimulation: Facts or Fiction? *Int J Mol Sci*. 2022;23(22):13775.
63. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, Kupsch A. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. *Exp Neurol*. 2008;210(1):257–60.
64. Spieles-Engemann AL, Behbehani MM, Collier TJ, Wohlgenant SL, Steece-Collier K, Paumier K, et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. *Neurobiol Dis*. 2010;39(1):105–15.
65. Spieles-Engemann AL, Steece-Collier K, Behbehani MM, Collier TJ, Wohlgenant SL, Kemp CJ, et al. Subthalamic nucleus stimulation increases brain derived neurotrophic factor in the nigrostriatal system and primary motor cortex. *J Parkinson's Dis*. 2011;1(1):123.

66. Duncan RP, Van Dillen LR, Garbutt JM, Earhart GM, Perlmutter JS. Physical therapy and deep brain stimulation in Parkinson's Disease: protocol for a pilot randomized controlled trial. *Pilot Feasibil Stud*. 2018;4(1):1–7.
67. Allert N, Cheeran B, Deuschl G, Barbe MT, Csoti I, Ebke M, et al. Postoperative rehabilitation after deep brain stimulation surgery for movement disorders. *Clin Neurophysiol*. 2018;129(3):592–601.
68. Bötzel K, Kraft E. Strategies for treatment of gait and posture associated deficits in movement disorders: the impact of deep brain stimulation. *Restor Neurol Neurosci*. 2010;28(1):115–22.
69. Munhoz RP, Picillo M, Fox SH, Bruno V, Panisset M, Honey CR, et al. Eligibility criteria for deep brain stimulation in Parkinson's disease, tremor, and dystonia. *Can J Neurol Sci* [Internet]. 2016;43(4):462–71.
70. Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, Stowe R, et al. Physiotherapy for Parkinson's disease: a comparison of techniques. *Cochrane Database Syst Rev*. 2014;2014(6):CD002815.
71. Yitayeh A, Teshome A. The effectiveness of physiotherapy treatment on balance dysfunction and postural instability in persons with Parkinson's disease: a systematic review and meta-analysis. *BMC Sports Sci Med Rehabil*. 2016;8(1):1–10.
72. Mehrholz J, Kugler J, Storch A, Pohl M, Elsner B, Hirsch K. Treadmill training for patients with Parkinson's disease. *The Cochrane database of systematic reviews* [Internet]. 22 agosto 2015 [citato 12 giugno 2022];(8). Disponibile su: <https://pubmed.ncbi.nlm.nih.gov/26297797/>
73. Schenkman M, Hall DA, Baron AE, Schwartz RS, Mettler P, Kohrt WM. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. *Phys Ther*. 2012;92(11):1395–410.
74. Rutz DG, Benninger DH. Physical therapy for freezing of gait and gait impairments in Parkinson disease: a systematic review. *PM&R*. 2020;12(11):1140–56.
75. Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. *Mov Disord*. 2013;28(9):1230–40.
76. Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. *JAMA Neurol*. 2018;75(2):219–26.
77. van der Kolk NM, de Vries NM, Kessels RPC, Joosten H, Zwiderman AH, Post B, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial. *Lancet Neurol*. 2019;18(11):998–1008.
78. Angelopoulou E, Anagnostouli M, Chrousos GP, Bougea A. Massage therapy as a complementary treatment for Parkinson's disease: a systematic literature review. *Complement Ther Med*. 2020;49: 102340.
79. Carmignano SM, Fundarò C, Bonaiuti D, Calabrò RS, Cassio A, Mazzoli D, et al. Robot-assisted gait training in patients with Parkinson's disease: implications for clinical practice. A systematic review-*IOS Press*. [citato 16 novembre 2024]; Disponibile su: <https://content.iospress.com/articles/neurorehabilitation/nre220026>
80. Bissolotti L, Isacco-Grassi F, Orizio C, Gobbo M, Berjano P, Villafañe JH, et al. Spinopelvic balance and body image perception in Parkinson's disease: analysis of correlation. *Eur Spine J*. 2015;24(7):898–905.
81. Ferrazzoli D, Ortelli P, Madeo G, Giladi N, Petzinger GM, Frazzitta G. Basal ganglia and beyond: the interplay between motor and cognitive aspects in Parkinson's disease rehabilitation. *Neurosci Biobehav Rev*. 2018;90:294–308.
82. Lageman SK, Mickens MN, Cash TV. Caregiver-identified needs and barriers to care in Parkinson's disease. *Geriatr Nurs*. 2015;36(3):197–201.
83. Dietz V. Proprioception and locomotor disorders. *Nat Rev Neurosci*. 2002;3(10):781–90.
84. Kitago T, Krakauer JW. Chapter 8-Motor learning principles for neurorehabilitation. In: Barnes MP, Good DC, curatori. *Handbook of Clinical Neurology* [Internet]. Elsevier; 2013 [citato 15 luglio 2024]. p. 93–103. (Neurological Rehabilitation; vol. 110). Disponibile su: <https://www.sciencedirect.com/science/article/pii/B9780444529015000083>
85. Hartmann CJ, Fliegen S, Groiss SJ, Wojtecki L, Schnitzler A. An update on best practice of deep brain stimulation in Parkinson's disease. *Ther Adv Neurol Disord*. 2019;12:1756286419838096.
86. Artusi CA, Lopiano L, Morgante F. Deep brain stimulation selection criteria for Parkinson's disease: time to go beyond CAPSIT-PD. *J Clin Med*. 2020;9(12):3931.
87. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. *Lancet Neurol*. 2012;11(5):429–42.
88. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. *Lancet Neurol*. 2008;7(7):605–14.
89. Zangaglia R, Pacchetti C, Pasotti C, Mancini F, Servello D, Sinforiani E, et al. Deep brain stimulation and cognitive functions in Parkinson's disease: a three-year controlled study. *Mov Disord*. 2009;24(11):1621–8.
90. Kim HJ, Jeon BS, Paek SH. Nonmotor symptoms and subthalamic deep brain stimulation in Parkinson's disease. *J Mov Disord*. 2015;8(2):83.
91. Bernasconi T, Biondi S, Calvo A, Chio A, Craig A, Dejonckere PH, et al. 20 Rehabilitative Approaches and Prognosis for Acquired Motor Speech Disorders: Dysarthria and Dyspraxia. In 2025 [citato 25 marzo 2025]. Disponibile su: https://doi.org/10.1007/978-3-031-48091-1_5
92. Jitkrisadakul O, Bhidayasiri R, Kalia SK, Hodaie M, Lozano AM, Fasano A. Systematic review of hardware-related complications of Deep Brain Stimulation: Do new indications pose an increased risk? *Brain Stimul*. 2017;10(5):967–76.
93. Guidetti M, Marceglia S, Loh A, Harmsen IE, Meoni S, Foffani G, et al. Clinical perspectives of adaptive deep brain stimulation. *Brain Stimul*. 2021;14(5):1238–47.
94. Marceglia S, Guidetti M, Harmsen IE, Loh A, Meoni S, Foffani G, et al. Deep brain stimulation: is it time to change gears by closing the loop? *J Neural Eng*. 2021;18(6):061001.
95. Priori A, Maiorana N, Dini M, Guidetti M, Marceglia S, Ferrucci R. Adaptive deep brain stimulation (aDBS). *Int Rev Neurobiol*. 2021;159:111–27.
96. Black N, Murphy M, Lamping D, McKee M, Sanderson C, Askham J, et al. Consensus development methods: a review of best practice in creating clinical guidelines. *J Health Serv Res Policy*. 1999;4(4):236–48.
97. Gottlieb M, Caretta-Weyer H, Chan TM, Humphrey-Murto S. Educator's blueprint: a primer on consensus methods in medical education research. *AEM Edu Training*. 2023;7(4): e10891.
98. Tenny S, Varacallo M. Evidence based medicine (EBM). Treasure Island: StatPearls Publishing; 2018.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.